Nearly 50 million women each year are projected to reach menopause by 2030. Many of these women will experience vasomotor symptoms such as night sweats and hot flashes as they enter the menopausal transition. Up until the release of the findings of the Women’s Health Initiative (WHI) studies, women were frequently prescribed hormone therapy (HT) to alleviate bothersome and sometimes debilitating menopausal symptoms as well as to prevent osteoporosis and coronary heart disease (CHD). Although the WHI studies were the first large, randomized, controlled trials that contradicted what was historically believed about the benefits of HT in postmenopausal women, important limitations including baseline demographics of WHI participants and investigation of only one HT strength/dosage form exist. HT may be a reasonable pharmacotherapy option for the management of menopausal symptoms following complete patient evaluation by experienced clinicians. Updated recommendations addressing management of menopausal symptoms, a new HT product containing the spironolactone-analogue drospirenone (DRSP), and discontinuation methods of HT are also discussed in this review.
GraciaCRSammelMDFreemanEW. Defining menopause status: creation of a new definition to identify the early stages of the menopausal transition. Menopause. 2005;12(2):128–135.
4.
ColNFFairfieldKMEwan-WhiteC. In the clinic. Menopause. Ann Intern Med. 2009;150(7):ITC4-1-15.
5.
KaseNG. Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement. Gend Med. 2009;6(suppl 1):37–59.
6.
SantoroN. The menopausal transition. Am J Med. 2005;118(suppl 12B):8S–13S.
7.
RingaV. Menopause and treatments. Qual Life Res. 2000;9(suppl 6):695–707.
8.
SoulesMRShermanSParrottE. Stages of reproductive aging workshop (STRAW). J Womens Health Gend Based Med. 2001;10(9):843–848.
9.
AlexanderIMMooreA. Treating vasomotor symptoms of menopause: the nurse practitioner’s perspective. J Am Acad Nurse Pract. 2007;19(3):152–163.
10.
ShenWStearnsV. Treatment strategies for hot flushes. Expert Opin Pharmacother. 2009;10(7):1133–1144.
11.
Estrogen and progestogen therapy in postmenopausal women. Fertil Steril. 2008;90(5 suppl):S88–S102.
12.
Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause. 2007;14(2):168–182.
13.
HickeyMDavisSRSturdeeDW. Treatment of menopausal symptoms: what shall we do now?Lancet. 2005;366(9483):409–421.
14.
GasM. Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy. Cleve Clin J Med. 2008;75(suppl 4):S13–S16.
15.
StuddJ. Second thoughts on the Women’s Health Initiative study: the effect of age on the safety of HRT. Climacteric. 2004;7(4):412–414.
16.
GreendaleGAReboussinBAHoganP. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestins trial. Obstet Gynecol. 1998;92(6):982–988.
17.
AACE Menopause Guidelines Revision Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Menopause. Endocr Pract. 2006;12(3):317–337.
18.
SchmidtJWWollnerDCurcioJ. Hormone replacement therapy in menopausal women: past problems and future possibilities. Gynecol Endocrinol. 2006;22(10):564–577.
19.
The Women’s Health Initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291(14):1701–1712.
20.
LamPOMChungTKHHainesC. Where are we with postmenopausal hormone therapy in 2005?Gynecol Endocrinol. 2005;21(5):248–256.
21.
HulleySGradyDBushT. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605–613.
22.
TanOHarmanSMNaftolinF. What can we learn from design faults in the Women’s Health Initiative randomized clinical trial?Bull NYU Hosp Jt Dis. 2009;67(2):226–229.
23.
RossouwJEAndersonGLPrenticeRLand Writing group for the Women’s Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321–333.
24.
HulleySBGradyS. The WHI estrogen-alone trial-do things look any better?JAMA. 2204;291(14):1769–1771.
25.
RossouwJEPrenticeRLMansonJE. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477.
26.
The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17(2):242–255.
27.
PalaciosSFoidartJMGenazzaniAR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 2006;55(4):297–307.
28.
ShurmannRHollerTBendaN. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric. 2004;7(2):189–196.
29.
LeeBSKangBMYoonBK. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007;57(4):361–369.
30.
ArcherDFThorneycroftIHFoeghM. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12(6):716–727.
SuffolettoJHessR. Tapering versus cold turkey: symptoms versus successful discontinuation of menospausal hormone therapy. Menopause. 2009;16(3):436–437.
33.
GradyDSawayaGF. Discontinuation of postmenopausal hormone therapy. Am J Med. 2005;118(suppl 12B):163S–165S.
34.
HaskellSBean-MayberryBGordonK. Discontinuing postmenopausal hormone therapy in an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?Menopause. 2009;16(3):494–499.
35.
Hormone products for postmenopausal use in the United States and Canada. Compiled by the North American Menopause Society, 2009.
